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Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammatory biomarker. Basic 
research has shown that Lp-PLA2 is involved in the pathogenesis of atherosclerosis. In the past 
decade, an increasing number of epidemiological studies have investigated the association of Lp-
PLA2 with atherosclerosis, but its roles in the different stages of atherosclerosis are not 
established. By undertaking a systematic review of the epidemiological studies on the relationship 
between Lp-PLA2 and atherosclerotic cardiovascular disease (CVD)/subclinical atherosclerosis, 
we tried to evaluate the relationship between Lp-PLA2 and the different stages of atherosclerosis. 
MEDLINE, Cochrane Library, and National Knowledge Infrastructure (CNKI) were searched up 
to September 1st, 2011. The references in all the located articles were manually searched. 
Epidemiological studies on the association of Lp-PLA2 with CVD and subclinical atherosclerosis, 
with total CVD, coronary heart disease (CHD), stroke, and subclinical atherosclerosis as their 
observation endpoints or outcome variables, were included in this study. Studies which did not 
assess the hazard ratio (HR), relative risk (RR), or odds ratio (OR) of Lp-PLA2 or which did not 
adjust for other known risk factors were excluded. The general information, study design, sample 
size, outcome variables and their definitions, follow-up duration, Lp-PLA2 measurements, 
variables adjusted in the multivariate analysis and main results in the literatures were retrieved. 
Thirty-nine studies were enrolled in this systematic review. Thirty-three studies (49, 260 subjects) 
investigated the relationship between Lp-PLA2 and CVD, among which 31 showed that increased 
Lp-PLA2 is associated to high risk for incidence or mortality of CVD: HR/RR per 1 standard 
deviation (SD) increase = 1.17–1.40; RR for the highest as compared with the lowest quartile was 
1.41–3.75 (1.8–2.5 in most studies). Six studies (four cross-sectional studies and two case-control 
studies, with an overall sample size of 5,537) explored the relationship between Lp-PLA2 and 
subclinical atherosclerosis; among them, two studies demonstrated that Lp-PLA2 was associated 
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with coronary artery calcification in young adults and men. In conclusion, many epidemiological 
studies have demonstrated that Lp-PLA2 increases the risk of clinical CVD events. However, 
whether there is a similar association between Lp-PLA2 and subclinical atherosclerosis remains 
unclear. Whether Lp-PLA2 exerts its effect during the occurrence of clinical events promoted by 
unstable plaques or at the early stage of atherosclerosis needs to be clarified in further prospective 
studies.
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INTRODUCTION
Atherosclerosis is a chronic, progressive and systemic pathologic process that frequently 
affects large- and medium-sized arteries, leading to severe cardiovascular disease (CVD) 
events such as coronary heart disease (CHD) and stroke. At least half million new events of 
myocardial infarction and 2 million new events of stroke occur in China annually.1 This 
may be explained by the unsatisfactory prevention and control of conventional risk factors 
such as dyslipidemias, smoking, hypertension, and diabetes mellitus (DM). Nevertheless, 
studies have demonstrated that these conventional risk factors cannot fully explain the 
occurrence and development of atherosclerosis,2 suggesting that there might be some 
emerging or novel risk factors of atherosclerosis. The pathological changes of 
atherosclerosis remain asymptomatic for decades before clinical events occur. Our previous 
study showed that one-third of Beijing residents aged 45–74 years have carotid plaques.3 
Therefore, further investigation of the risk factors of subclinical atherosclerosis will be 
important for the early prevention and treatment of CVD.
Accumulated evidence has demonstrated that inflammatory reactions have key roles in the 
pathogenesis of atherosclerosis. Among various inflammatory factors, C-reactive protein 
(CRP) has been the most widely studied and confirmed to be associated with CVD. 
However, due to the lack of evidence from clinical trials, whether CRP can be treated as a 
therapeutic target remains uncertain. Furthermore, the atherosclerosis-related inflammatory 
reaction is a complex process involving multiple factors. For decades, scientists devoted 
untiring effort to discover more sensitive and more specific factors that cause 
atherosclerosis, with attempts to find new targets that can be used for the prevention and 
treatment of CVD. In recent years, the novel inflammatory biomarker lipoprotein-associated 
phospholipase A2 (Lp-PLA2) has been found to be associated with the occurrence and 
development of atherosclerosis.
Lp-PLA2 is an enzyme produced and secreted by monocyte-macrophages, T-lymphocytes, 
and other inflammatory cells. As a member of the phospholipase superfamily, it is also 
termed “platelet-activating factor acetylhydrolase (PAF-because of its ability to degrade 
platelet-activating factor (PAF) by hydrolysis of the sn-2 acetyl group. In humans, 80% of 
binds with low-density lipoprotein (LDL), 15%–20% with high-density lipoprotein (HDL), 
and the remaining with very-low-density lipoprotein (VLDL) and lipoprotein(a). In the 
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circulation, hydrolyzes oxidized phosphatidylcholines in LDL, and produces lysophosphati-
dylcholine and oxidized free fatty acids, two highly pro-inflammatory molecules. Research 
has shown that these hydrolyzed products can up-regulate the expressions of adherence 
factors and cytokines, as well as promote monocytes to aggregate from the lumen into the 
intima, where they develop into macrophages and lead to the formation of atherosclerotic 
plaques. Lysophosphati-dylcholine can also promote the release of arachidonic acid, which 
can affect the diastolic function of the vascular endothelium and induce cellular apoptosis, 
and thus damage the vascular endothelial cells and their protective mechanisms. As a result, 
the local inflammatory reaction becomes aggravated and plaques form.4 Using combined in 
situ hybridization and immunocytochemistry, researchers have detected Lp-PLA2 in 
atherosclerotic lesions in humans and rabbits. In addition, approximately six-fold higher 
activity was detected in the atherosclerotic aortas of Watanabe heritable hyperlipidemic 
rabbits compared with normal aortas from control rabbits.5 All findings indicate that Lp-
PLA2 may play an important part during atherosclerosis. An increasing number of 
epidemiological studies have investigated the association of Lp-PLA2 with atherosclerosis in 
the past decade, and have been reviewed to a certain extend in the literature.6–11 However, 
most of the published reviews are traditional reviews, while only five systematic reviews 
(including meta-analyses) are available. The first two systematic reviews summarized the 
impact of Lp-PLA2 levels on CVD in epidemiological studies, but the impacts on different 
types of CVD (CHD or stroke) were not reviewed,12–13 while meta-analyses published by 
Casas JP, et al and Zheng GH, et al focused on the impact of genetic polymorphisms on 
CHD.14–15 The Lp-PLA2 Studies Collaboration conduced the largest meta-analysis and 
evaluated the association between plasma Lp-PLA2 with both CHD and stroke.16 However, 
none of the above systematic reviews have summarized the effect of Lp-PLA2 on subclinical 
atherosclerosis. By carrying out systematic reviews on epidemiological studies focusing on 
the relationship between Lp-PLA2 and different types of atherosclerotic cardiovascular 
disease/subclinical atherosclerosis, we tried to evaluate the relationship between Lp-PLA2 
and the different stages of atherosclerosis.
MATERIALS AND METHODS
Inclusion and exclusion criteria Epidemiological studies on the association of with total 
CVD, coronary heart disease (CHD), stroke, and subclinical atherosclerosis as their 
observation endpoints or outcome variables, were included in this study. Studies which did 
not assess the hazard ratio (HR) or relative risk (RR) of Lp-PLA2 or which did merely 
univariable analysis and did not adjust for any other known risk factors (e.g., Framingham 
risk factors, including age, sex, smoking, blood pressure, diabetes, LDL-C, and HDL-C) 
were excluded.
Search strategy MEDLINE (from 1 January 1970), Cochrane library and National 
Knowledge Infrastructure (CNKI) were searched up to September 1st, 2011. All references 
in located articles were manually searched. We searched MEDLINE using the MeSHs of 
Cardiovascular Diseases OR atherosclerosis, AND the term “lipoprotein associated 
phospholipase A2” in all fields. In Cochrane library and CNKI, we used “lipoprotein 
associated phospholipase A2” in all fields or “Lp-PLA2” in title to search. In addition, we 
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checked the related references and complemented to the searching results. Only publications 
in English or Chinese were searched.
Review method all literature search results were imported into reference manager software 
with which excluded the repeated articles by checking the titles and authors. In addition, 
reviews and articles based on the same study data being published in different journals were 
excluded manually by reading the abstracts. We obtained the remains full text and identified 
the final including literatures which meet the criteria.
Reading the included articles, we extract the following information: authors, published year, 
study design, sample size, outcome variables and the definition, follow-up time (except 
case-control and cross-sectional studies), Lp-PLA2 measurements, adjusted variables and 
main results in multivariate statistical analysis. Results data were mainly represented using 
RR, HR or OR and its 95% confidence interval (CI)
RESULTS
Results of the Literature Search
One hundred eighty nine English-language and 32 Chinese-language publications were 
identified. Eight of them that were repeatedly included from more than one search databases 
were excluded. Eighty seven review articles and one duplicated publication were further 
excluded after the careful review of the abstracts. Among the remaining 125 articles, 64 did 
not report CVD or subclinical atherosclerosis outcomes, 22 did not assess the relationship 
between and CVD/subclinical atherosclerosis or conduct statistical analyses without 
adjusting for any known risk factors of CVD. Thirty nine studies are included in the final 
analysis (Figure 1).
Basic Information of the Enrolled Studies
Thirty-three articles on the relationship between and clinical CVD events were retrieved: 21 
prospective cohort studies (Table 1),17–37 6 case cohort studies/nested case control studies 
(Table 2),38–44 and 5 case control studies (Table 3).45–49 Among these 33 publications, 15 
articles were on total CVD18–20,22–26,28–30,33–35,39 (among which 1 article was also on 
CHD25 and 1 article was also on stroke20), 17 articles were on 
CHD17,21,25,27,31–32,36–38,40,42,44–49 (among which 1 article was also on total CVD25 and 1 
article was also on stroke32), and 4 articles were on stroke20,32,41,43 (among which 1 article 
also on total CVD20 and 1 article was also on CHD32). In total, 49, 260 subjects were 
enrolled in these 33 studies, among which 3 studies were done only among males17,33,38 and 
3 only among females.39,43–44 In the remaining 27 studies, males accounted for over 50% in 
17 studies. The age range of study subjects was from 21 to 84 years. Most of them were 
Caucasians, African Americans, Hispanics, and Asians (Koreans and Chinese). The length 
of follow-up ranged from 42 days to 18 years for the prospective studies. Fourteen studies 
measured Lp-PLA2 concentrations, 13 detected its activities, and 6 determined both 
measurements. All studies carried out multivariate analyses and adjusted for all or some of 
the Framingham risk factors, including age, sex, smoking status, systolic blood pressure 
(SBP), DM, LDL-C, and HDL-C. Among them, 24 studies adjusted for CRP level.
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Six articles (with a sample size of 5,537 subjects) on the relationship between and 
subclinical atherosclerosis were retrieved,50–55 including two case control studies50,55 and 
four cross-sectional studies.51–54 Among the six studies, one study only measured mass, 3 
only measured Lp-PLA2 activities, and 2 had determined both measurements.
Relationship between Lp-PLA2 and Atherosclerosis
Association of with CVD events—Among the 33 studies, 31 showed a positive 
association between increased Lp-PLA2 and high risk for incidence or mortality of total 
CVD, CHD or stroke: hazard ratio/relative risk (HR/RR) per 1 standard deviation (SD) 
increase = 1.17–1.40; the RR or OR for the highest as compared with the lowest quartile was 
1.41–3.75 (1.8–2.5 in 16studies). The remaining two did not find an association between Lp-
PLA2 and CVD.25,39 Based on the observation endpoints or outcome variables, these 33 
studies could be divided into the three categories described below.
Relationship between Lp-PLA2 and Total CVD
Of the 15 studies on the association between Lp-PLA2 and total CVD, 14 were prospective 
cohort studies, all of which had positive findings. The Malmo study from Sweden was the 
only study that examined first incident CVD event as all study subjects were free of CVD at 
baseline. After 10 years of follow-up, the risk of CVD events for the highest tertile of Lp-
PLA2 was 1.46-times (95% confidence interval (CI): 1.01–2.13) of that for the lowest.29 Lp-
PLA2 was found to significantly increased the risk of recurrent CVD events in 8 cohort 
studies of all the patients with existing CVD at the baseline.20,22–24,26,30,33–34 The 
remaining five studies enrolled both patients with and without CVD at the baseline. Their 
results showed that high baseline Lp-PLA2 is associated with increased risk of the both first 
and recurrence CVD events.18–19,25,28,35 However, no association was found between Lp-
PLA2 and total CVD in one nested case-control study based on the Women’s Health Study 
(WHS).39
Relationship between Lp-PLA2 and CHD
Among seventeen studies (eight cohort studies, four nested case-control studies or case-
cohort studies, and five case-control studies) that examined the relationship between Lp-
PLA2 and CHD, 15 showed positive findings. However, two other studies showed that the 
association was no longer statistically significant after the other risk factors (especially 
cholesterol) were adjusted.25,32
Of eight cohort studies, five enrolled subjects free of CVD at baseline.17,31–32,36–37 High 
Lp-PLA2 was found to be associated with increased risk of incident CHD in three 
studies.17,31,37 In one of the studies among patients with type 1 diabetes,36 the association 
was only found in patients with specific genotypes. In another study Lp-PLA2 was 
associated with stroke but not with CHD.29 In one study among patients with history of 
myocardial infarction, the risk of recurrent CHD increased by 90% (95% CI: 31%–175%) in 
patients with the highest quartile of Lp-PLA2 compared with those with the other three 
quartiles combined.21 Of two studies that enrolled both patients with and without existing 
CVD, one showed that high Lp-PLA2 was associated with increased risk for CHD deaths,27 
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while no association was found in the other study after adjustment of LDL-C, HDL-C, and 
TG.25
All the four nested case-control study on the relationship between Lp-PLA2 and CHD 
demonstrated that high Lp-PLA2 increased the risk of CHD.38,40,42,44 The study by Packard 
et al. was the first population-based epidemiological study on the relationship between Lp-
PLA2 and CVD.38 Framingham risk factors and CRP were adjusted in all these three studies. 
The RR for each increased SD of Lp-PLA2 was 1.18 (95% CI = 1.05–1.33); RR ranged from 
1.97 to 2.08 for the highest tertile/quartile versus the lowest).
There were five case-control studies on the relationship between Lp-PLA2 and CHD,45–49 in 
which all the patients were confirmed to have CHD by coronary angiography. All these five 
studies demonstrated that Lp-PLA2 was associated with CHD (OR range of 1.39–1.92 for 
the highest quartile versus the lowest).
Relationship between Lp-PLA2 and Stroke
Four studies on the relationship between Lp-PLA2 and stroke were retrieved. All four 
studies demonstrated that Lp-PLA2 was associated with the incidence or recurrence of 
ischemic stroke.20,32,41,43 Two of the four were prospective cohort studies.
One study tracked subjects without CVD at the baseline for 10 years and found that 
increased Lp-PLA2 activity was significantly associated with the risk of stroke (RR = 1.94 
for the highest tertile versus the lowest; 95% CI = 1.15–3.26) after the influence of 
conventional risk factors and CRP was adjusted for. The concentration of Lp-PLA2 had a 
similar association with stroke (RR = 1.92 for the highest tertile versus the lowest; 95% CI = 
1.20–3.10). In another study, 467 first-ever stroke patients was followed for 5 years, A 
strong association between increased Lp-PLA2 concentration and high risk of stroke 
recurrence was reported (HR = 2.08 for the highest quartile versus the lowest; 95% CI = 
1.04–4.18).20 The positive association was also found in one case cohort study and one 
nested case-control.41,43
Relationship between Lp-PLA2 and Subclinical Atherosclerosis
The relationship between Lp-PLA2 and subclinical atherosclerosis was observed in six 
studies (Table 4),50–55 among which four were cross-sectional studies51–54 and two case-
control studies.50, 55 Coronary artery calcification (CAC) was used as an indicator for 
assessing subclinical atherosclerosis in four studies. Carotid plaques and intima-media 
thickness (IMT) was used in two studies.51, 55 Increased Lp-PLA2 was found to be 
associated with high risk of CAC in the case-control study of young adult population (OR = 
1.28; 95% CI, 1.03–1.60).50 The association of increased Lp-PLA2 with subclinical 
atherosclerosis was present if only the age was adjusted but disappeared if the cholesterol 
level was adjusted, according to the Rotterdam Study.51–52 Lp-PLA2 was associated with 
CAC only in men but not in women from the Dallas Heart Study.53 No independent 
association between Lp-PLA2 and subclinical atherosclerosis was found in patients with 
long-term DM54 or patients with metabolic syndrome.55
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This systematic review suggests that Lp-PLA2 is closely associated with CVD events from 
overwhelming majority of published studies. High Lp-PLA2 was associated with increased 
risk for both first and recurrence of total CVD, CHD, and ischemic stroke. To understand 
the role of Lp-PLA2 in the early prevention and treatment of CVD, elucidating the 
relationship between Lp-PLA2 and subclinical atherosclerosis is very important. Studies on 
the relationship between Lp-PLA2 and subclinical atherosclerosis are limited. Most of 
previous studies were cross-sectional or case-control in nature and often showed conflicting 
results.
Among 33 studies on the relationship between Lp-LPA2 and CVD in this review, 31 studies 
demonstrated that increased Lp-PLA2 could remarkably increase CVD risk. More 
specifically, of 17 studies that investigated the relationship between Lp-PLA2 and CHD, 15 
showed that increased Lp-PLA2 increased the risk of CHD; of four studies that investigated 
the relationship between Lp-PLA2 and ischemic stroke, all showed that increased Lp-PLA2 
increased the risk of ischemic stroke; and, of 15 studies that investigated the relationship 
between Lp-PLA2 and total CVD, 14 showed that increased Lp-PLA2 increased the risk of 
total CVD. Some other studies did not find an association of Lp-PLA2 with CVD, which 
may be explained by the two main reasons. First, subjects had certain underlying diseases 
and the studies had too many confounding factors. For example, in the study by Allison et 
al., 508 individuals underwent examinations of arteries of the lower limbs;25 and in the 
study by Miller et al., 96 patients with type 1 DM and microalbuminuria were assessed.36 
Therefore, no positive results were obtained from these two studies. Secondly, sample sizes 
were small and subjects belonged to low-risk populations. For example, in the study by 
Blake et al., only 123 female patients with CVD and 123 female normal controls were 
enrolled.39 Female patients tend to have fewer risk factors for CVD and some of the women 
in that study used estrogen, so the results could have been confounded. Furthermore, the 
inconsistent spectrum of disease in the study groups (which may include CHD or stroke) can 
dramatically influence results (especially for case-control studies with relatively small 
sample sizes).
Majority of the studies demonstrated the association of Lp-PLA2 with CVD events. CVD 
events are end-stage clinical manifestations of atherosclerosis. The initiation of the 
pathological changes of atherosclerosis usually starts decades prior to the occurrence of 
clinical events. Whether Lp-PLA2 exerts its effect during the development of clinical events 
due to unstable plaques or at the early stage of atherosclerosis remains unclear. Although 
many studies have shown a relationship between Lp-PLA2 and clinical events, the 
association between Lp-PLA2 and subclinical atherosclerosis is uncertain. One hypothesis 
for this inconsistency is that the role of Lp-PLA2 in the development of atherosclerosis is 
different from its role in the occurrence of clinical CVD events. In fact, Kolodgie et al. 
investigated the expression of Lp-PLA2 in coronary segments from 25 sudden coronary 
death patients, and found that early plaques do not stain intensely for Lp-PLA2 whereas 
rupture-prone and ruptured plaques demonstrated intense Lp-PLA2 staining, suggesting that 
Lp-PLA2 might be a trigger of clinical events through plaque instability and rupture, but not 
an initiator of early development of atherosclerosis. Another possible explanation for the 
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different findings from studies on clinical events and subclinical atherosclerosis is the 
difference in study designs. The association between Lp-PLA2 and the development of 
clinical CVD events have been consistently shown by a number of prospective cohort 
studies, but few prospective studies has tested its association with the development of 
subclinical atherosclerosis. Ongoing studies have been mostly cross-sectional or case-
control studies which are less powerful compared with prospective studies in hypothesis 
testing. As these studies used only one cross-sectional measurement for subclinical 
atherosclerosis, elucidation of its association with Lp-PLA2 may not be possible. 
Prospective cohort studies are required to identify the relationship between Lp-PLA2 and 
subclinical atherosclerosis. Additionally, most studies have been conducted in European and 
American populations,50–54 and only one study with limited sample size has investigated the 
relationship between Lp-PLA2 and subclinical atherosclerosis in Chinese population.55 
Whether there is any ethnic variety in the relationship is still unknown.
We also reviewed the pre-analytical phase and assay method for the studies included in the 
current study. Among the 39 studies, blood samples were collected at fasting stage in all but 
5 studies,17,39,42,51–52 and plasma were used for Lp-PLA2measurements in all but 4 
studies.20,31,37,50 Lp-PLA2 mass was assayed using a commercial ELISA kit (PLACIor 
PLACII) in 21 of 23 studies where Lp-PLA2 mass were measured (including 8 studies 
measured both Lp-PLA2 mass and activity). An in-house ELISA was used in the remaining 
two studies.38–39 Lp-PLA2 activity was measured in 24 studies, among which a colorimetric 
activity method was used in 16 studies, while a radiometric assay was applied in eight other 
studies.23,29,32,42,45,48,51–52 Although the association between Lp-PLA2 and CVD was 
rather consistent across the studies, the mean values of Lp-PLA2 mass or activity varied 
considerably in different assays. An ELISA test has been cleared by the US Food and Drug 
Administration to be used in conjunction with clinical evaluation and patient risk assessment 
as an aid in predicting the risk of CVD.56
In summary, high Lp-PLA2 is associated with increased risk of clinical CVD events, while 
the association between Lp-PLA2 and subclinical atherosclerosis remains uncertain. Further 
prospective cohort studies on the relationship between Lp-PLA2 and subclinical 
atherosclerosis are warranted to determine whether Lp-PLA2 may only play a role in the 
progression of subclinical atherosclerosis to clinical events or both the initiation of the 
atherosclerosis and the progressions towards to clinical outcomes.
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